Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02858921 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Study acronym: Neo Trio
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Aug 24, 2026 Completion date: Nov 2024 to Nov 2027 · Secondary endpoints: 14 to 15 · Primary endpoint revised · 1 morev18 Show 4 more changesShow less
    • Completion date: Nov 2024 to Nov 2027
    • Secondary endpoints: 14 to 15
    • Primary endpoint revised
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv17
  3. Primary completion date changed from estimate of Nov 2021 to Jan 2, 2022v16
  4. Trial status: Recruiting to Active, Not Recruiting Site details revised at 3 of 3 sitesv15 Show 1 more changeShow less
    • Site details revised at 3 of 3 sites
  5. Re-verified, no change to tracked fieldsv14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: Nov 2020 to Nov 2021v13
  2. Primary completion date: Nov 2019 to Nov 2020 Completion date: Nov 2020 to Nov 2024v12 Show 1 more changeShow less
    • Completion date: Nov 2020 to Nov 2024
  3. Site contacts updated at 1 of 3 sitesv11
  4. Site contacts updated at 1 of 3 sitesv10
  5. Study sites: 2 to 3v9
  6. Primary completion date: Nov 2018 to Nov 2019 Completion date: Nov 2019 to Nov 2020 · Secondary endpoints: details revised at 12 of 14 entries · Study description shortened, about 35 words · 2 morev8 Show 5 more changesShow less
    • Completion date: Nov 2019 to Nov 2020
    • Secondary endpoints: details revised at 12 of 14 entries
    • Study description shortened, about 35 words
    • Site details revised at 2 of 2 sites
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  7. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jun 2018 to Nov 2018 · Completion date: Jun 2019 to Nov 2019 · Start date changed from estimate of Oct 2017 to Nov 8, 2017 · 1 morev7 Show 4 more changesShow less
    • Primary completion date: Jun 2018 to Nov 2018
    • Completion date: Jun 2019 to Nov 2019
    • Start date changed from estimate of Oct 2017 to Nov 8, 2017
    • Site details revised at 2 of 2 sites
  8. Start date: May 2017 to Oct 2017v6
  9. Re-verified, no change to tracked fieldsv5
  10. Start date: Feb 2017 to May 2017 Secondary endpoints: details revised at 13 of 14 entriesv4 Show 1 more changeShow less
    • Secondary endpoints: details revised at 13 of 14 entries
  11. Start date: Nov 2016 to Feb 2017 Site details revised at 2 of 2 sitesv3 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
  12. Study title shortened, about 2 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.
Trial Details
NCT Number NCT02858921
Lead Sponsor Melanoma Institute Australia
Collaborators: Merck Sharp & Dohme LLC, Novartis
Conditions Melanoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov